Indaptus Therapeutics Inc INDP 深 滬
已收盤 01-09 16:00:00 美东时间
3.13
+0.130
+4.33%
華盛通- 最 高3.1999
- 今 開2.98
- 成交量 21.96万股
- 最 低 2.9301
- 昨 收 3.00
- 總市值 346.33万
- 52周最高 47.60
- 市盈率 靜 --
- 換手率 19.84%
- 52周最低 1.65
- 委 比 -54.56%
- 總股本 110.65万
- 歷史最高 21952.00
- 量 比 1.17
- 振 幅 8.99%
- 歷史最低 2.41
- 每 手 1
- 風險率 7.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What Does the Market Think About Indaptus Therapeutics Inc?
Indaptus Therapeutics Inc's (NYSE:INDP) short interest as a percent of float ha...
2025-12-26 04:00
Market-Moving News for December 24th
PATH: 8% | UiPath To Replace Synovus Financial In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Friday, January 2; Versant Media Group To Replace Brandywine Realty Trust In The S&P Smallcap
2025-12-24 20:20
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 63.6% to $3.19 during W...
2025-12-24 20:05
Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket
Shares of Multi Ways Holdings Ltd (NYSE:MWG) rose sharply in pre-market trading...
2025-12-24 19:01
Indaptus Therapeutics Q3 EPS $(2.98) Beats $(4.17) Estimate
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(2.98) per share which beat the analyst consensus estimate of $(4.17) by 28.54 percent. This is a 67.04 percent increase over losses of $(9.04) per share
2025-11-12 21:35
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
Shares of CSX Corp (NASDAQ:CSX) rose sharply in pre-market trading after the co...
2025-10-17 17:55
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
2025-09-27 01:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
2025-09-05 05:13
Indaptus Reports Partial Response From Decoy20 Monotherapy In Urothelial Cancer; Combo With PD-1 Inhibitor Shows Favorable Safety
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agentNEW YORK,
2025-09-05 04:02
Indaptus Therapeutics Provides Clinical Update
Indaptus Therapeutics announced updates on their INDP-D101 clinical trial for Decoy20, a potential cancer treatment. In monotherapy, a patient with urothelial cancer and liver metastases experienced partial response, though disease progression led to discontinuation. In combination with PD-1 inhibitor tislelizumab, safety profiles align with each agent. Initial data on 7 patients in the combination cohort show varied outcomes. Financially, the co...
2025-09-04 20:01
